Corindus Announces 100th Robotic-Assisted PCI Procedure Performed Using 2nd Generation CorPath® GRX System

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS) announced today the milestone of the 100th robotic-assisted percutaneous coronary intervention (PCI) case performed using the Company’s second-generation CorPath GRX System. Since its commercial launch in January 2017, the CorPath GRX System has been used successfully in a variety of procedural settings and physicians have reported an increase in the number of procedures that can be performed robotically.

Sunil Rao, MD, Section Chief of Cardiology at the Durham VA Medical Center, stated, “The CorPath GRX System is an important advancement in the field of interventional cardiology and I am pleased to be a part of the initial launch of this enhanced technology. The addition of active guide management has allowed me to increase the number of interventional procedures I perform robotically, and as a result, I was able to complete several difficult cases entirely using the CorPath GRX System.”

The CorPath GRX System offers improvements in procedural control, enhanced workflow and radiation protection for physicians, patients and staff. Since its commercial launch, the CorPath GRX System has been used successfully in a variety of PCI cases including complex multi-vessel disease, NSTEMI, left radial access, diffused and calcified lesions, FFR, ostial RCA and subtotal 99% occlusions.

“The completion of the first 100 cases using our CorPath GRX System represents a significant milestone for Corindus,” said Mark Toland, President and CEO of Corindus. “The early feedback from our customers has been positive and we are excited to continue our U.S. commercial roll-out throughout the rest of this year.”



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.